Table 2.

The Role of SOCS3 in Targeted Therapy

Type of cancer	In Vitro/In Vivo/ Clinical	Combination	Mechanism of Action	Reference
T-cell neoplasms	In Vitro  + Clinical	Ruxolitinib + SOCS3↑	JAK/STAT↓	[41]
AML	In Vitro	TQ + SOCS3↑	JAK/STAT↓	[183]
HCC	In Vitro	SOCS3↓ + pomegranate	IL-6-STAT3 ↓	[184]
	In Vivo	OCA + SOCS3↓	STAT3↓	[122]
	In Vitro  + In Vitro	Arsenic and benzo[a]pyrene + SOCS3↓ →	Akt, Erk1/2 ↑	[121]
BC	In Vivo	UTMD + SOCS3↑	STAT↓	[107]
	In Vitro  + In Vitro  + Clinical	KLF14 + SOCS3↑	RhoA/Rock/STAT3 ↓	[67]
CRC	In Vivo	AhR + SOCS3↑	IL22↓	[69]
	In Vivo	Evolocumab + SOCS3↑ PCSK9 + SOCS3↓	PCSK9↓; JAK2/STAT3↑	[174]
	In Vitro  + Clinical	FU and OXA + SOCS3↓	PD-L1↓	[124]
	In Vitro  + In Vivo	OCA + SOCS3↑ →	JAK2/STAT3↓	[185]
PDAC	In Vitro  + Clinical	Gemcitabine + SOCS3↓ →	EZH2↑	[111]